Annual report pursuant to Section 13 and 15(d)

Balance Sheet Account Details - Contingent Liabilities (Details)

v3.10.0.1
Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Business Acquisition [Line Items]    
Revenue royalty payable on all Cydex-related revenue (as a percent)   20.00%
Cydex-related revenue amount that triggers royalty payments   $ 15,000,000.0
Additional revenue royalty payable when higher threshold of Cydex-related revenue met (percent)   10.00%
Cydex-related revenue amount that triggers additional royalty payments   $ 35,000,000.0
Contingent Liability [Roll Forward]    
Commercial rights at beginning of period $ 14,000,000 8,100,000
Payments (4,925,000) (5,000,000)
Fair Value Adjustment 3,426,000 2,500,000
Additions   8,400,000
Commercial rights at end of period 12,501,000 14,000,000
Cydex    
Contingent Liability [Roll Forward]    
Commercial rights at beginning of period 1,600,000 6,600,000
Payments (25,000) (5,000,000)
Fair Value Adjustment (1,050,000) 0
Additions   0
Commercial rights at end of period 525,000 1,600,000
Metabasis    
Contingent Liability [Roll Forward]    
Commercial rights at beginning of period 4,000,000 1,500,000
Payments (3,900,000) 0
Fair Value Adjustment 5,400,000 2,500,000
Additions   0
Commercial rights at end of period 5,500,000 4,000,000
Crystal    
Contingent Liability [Roll Forward]    
Commercial rights at beginning of period 8,400,000 0
Payments (1,000,000) 0
Fair Value Adjustment (924,000) 0
Additions   8,400,000
Commercial rights at end of period $ 6,476,000 $ 8,400,000